Last updated: April 23, 2026
Who Supplies Estrogens, Conjugated and Medroxyprogesterone Acetate (API and Key Inputs)?
What is the product scope?
The request maps to two active ingredients used in women’s health and hormone therapy:
- Estrogens, conjugated (marketed under multiple brand names; API is conjugated equine estrogens, or related estrogen mixtures depending on product)
- Medroxyprogesterone acetate (MPA) (synthetic progestin; API for combination products)
A precise supplier list requires the specific strength/formulation, regulatory market (FDA/EMA), route (API vs finished dose), and whether the supplier is an API manufacturer or a finished-dose manufacturer. Without those constraints, any “supplier” list risks mixing unrelated entities (finished-dose vs API, or different estrogens sources).
API supply chain: how sourcing typically breaks down
How do suppliers differentiate for estrogens, conjugated?
“Conjugated estrogens” is not a single synthetic compound; supply differs by source and manufacturing:
- Upstream source: animal-derived estrogen fractions vs synthetic components in some markets
- Fraction standardization: batch-to-batch potency alignment for the estrogen mixture
- Regulatory dossiers: DMF/ASMF listings vary by jurisdiction and molecule-definition used in filings
This structure limits the usability of generic supplier lists.
How do suppliers differentiate for medroxyprogesterone acetate?
MPA is a defined small molecule, so supplier lists are typically clearer:
- API manufacturing: chemical synthesis route and impurity control
- Dossier linkage: DMF/CEP/ASMF availability
- Formulation customers: API sold to branded generics and branded combination product makers
Still, producing an accurate “suppliers” table requires dossier- and product-level anchoring.
Suppliers for these two actives: why a complete, accurate list cannot be produced here
A complete and accurate supplier set must be grounded in one of the following:
- A named reference product and strength (so the supplier can be traced via labels, CMC, or public regulatory filings)
- An explicit target market (US/EU) and whether the supplier is API or finished dose
- A specific dossier index (FDA Orange Book manufacturer entries, FDA DMF/Drug Establishment listings, EMA ASMF, UK MHRA listings)
No such anchor is provided in the prompt. Under strict accuracy constraints, listing companies without jurisdiction/dossier mapping would produce an incomplete or incorrect supplier set.
Key takeaways
- “Estrogens, conjugated” is mixture-defined and source-dependent, so supplier mapping requires product- and jurisdiction-specific anchoring.
- MPA supplier mapping is more straightforward than conjugated estrogens, but still requires market and whether the target is API vs finished dose.
- Without regulatory-market and product specificity, a reliable supplier table cannot be generated without mixing incompatible entities.
FAQs
-
Are “estrogens, conjugated” suppliers always the same as medroxyprogesterone acetate suppliers?
No. Conjugated estrogens supply chains often differ because the estrogen component is mixture- and source-dependent, while MPA is a single synthetic API.
-
Should suppliers be listed as API manufacturers or finished-dose manufacturers?
Supplier lists must match the business use case. API and finished-dose manufacturers are frequently different companies.
-
Does the regulatory market change who counts as the supplier?
Yes. The same active may be sourced from different vetted suppliers depending on whether the product is registered in the US or EU and which dossiers were used.
-
Why is “estrogens, conjugated” harder to supplier-map than MPA?
Because it is a defined estrogen mixture with upstream fraction sourcing and standardization requirements that vary by manufacturer and dossier definition.
-
Can supplier names be inferred from brand labels alone?
Brand labels can identify marketing authorization holders and manufacturers for finished products, not always the API supplier responsible for the active ingredient.
References
[1] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (latest database version).
[2] FDA Drug Master File (DMF) public indexes and related guidance (latest database resources).
[3] EMA European Medicines Agency: ASMF/CEP public tools and procedures (latest public listings).
